CNSide® may catalyze LM treatment initiation, allow physicians to adapt treatment with real time shifts in tumor biology, and enable personalized cancer therapy HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) ...
Plus Therapeutics, Inc. announced that its subsidiary, CNSide Diagnostics, will present data at the SNO/ASCO CNS Metastases Conference from August 14-16, 2025, in Baltimore, MD. The presentations will ...
CHICAGO -- Intracerebroventricular (ICV) delivery of bivalent CAR T-cells targeting EGFR and IL13Rα2 was feasible and appeared safe in patients with recurrent glioblastoma (GBM) in a phase I study ...
A chain of immune reactions in the gut—driven by a key signaling protein and a surge of white blood cells from the bone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback